/* ========================================================= ProductFAQs.jsx — per-product FAQ content + PDP component ========================================================= */ /* Per-slug FAQ arrays. Each product has 4–5 Q&A pairs. These are also read by seo.js to emit FAQPage JSON-LD. */ const PRODUCT_FAQS = { 'bpc-157': [ { q: 'What purity standard does Clarion\'s BPC-157 meet?', a: 'Every lot of BPC-157 we release is tested by reverse-phase HPLC with acceptance criteria of ≥99.0% main-peak area. Lot CP2604-A01 released at 99.4%. Each vial ships with the lot-specific COA, and the full chromatogram is available on request.' }, { q: 'How should BPC-157 be stored and reconstituted?', a: 'Lyophilized BPC-157 is stable at −20°C for up to 24 months in its sealed vial. For research use, reconstitute with bacteriostatic water or sterile saline; post-reconstitution, store at 2–8°C and use within 30 days. See our peptide storage guide for full stability data.' }, { q: 'Is BPC-157 approved for human use?', a: 'No. BPC-157 is sold strictly as a reference compound for in-vitro research. It is not FDA-approved for any therapeutic indication and is not intended for human or veterinary use. Clarion labels every vial "For Research Use Only" and verifies research-context eligibility at checkout.' }, { q: 'Do you test every lot, or rely on supplier certificates?', a: 'We commission independent release testing per USP <1226> on every lot before it leaves our facility. Supplier documentation is not sufficient — we run identity, purity, content, water, acetate, sterility, and endotoxin assays in parallel.' }, { q: 'What is the sequence and molecular weight of BPC-157?', a: 'BPC-157 is a 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with molecular formula C62H98N16O22 and molecular mass 1419.55 g/mol. It is typically supplied as the acetate salt.' }, ], 'tb-500': [ { q: 'What fragment of thymosin β-4 is TB-500?', a: 'TB-500 is the 43-amino-acid synthetic fragment corresponding to the active region of thymosin β-4, containing the actin-binding domain. Molecular formula C212H350N56O78S, mass 4963.44 g/mol. It is supplied lyophilized as the acetate salt.' }, { q: 'How does TB-500 differ from full-length thymosin β-4?', a: 'TB-500 retains the actin-binding motif but is shorter and more chemically stable than the 44-residue native thymosin β-4 peptide. In in-vitro comparison assays, the fragment shows equivalent actin-sequestering activity at lower synthesis cost, which is why most research labs work with the fragment.' }, { q: 'What does HPLC purity > 99% actually mean?', a: 'It means the main chromatographic peak accounts for ≥99.0% of total peak area at the specified wavelength, with no single impurity peak exceeding 0.5%. Read our full guide on HPLC purity vs peptide content for why both numbers matter.' }, { q: 'Can TB-500 be co-formulated with BPC-157?', a: 'Yes — we offer a BPC + TB Combo vial (5mg + 5mg) for researchers running parallel in-vitro assays. The two peptides are chemically compatible in lyophilized form and in standard aqueous buffers.' }, { q: 'What shipping conditions preserve TB-500?', a: 'Lyophilized TB-500 ships in insulated packaging with the vial at ambient temperature (stable for 7+ days in lyophilized form). Upon receipt, transfer to −20°C. Cold-chain shipping is available on request for international orders.' }, ], 'bpc-tb-combo': [ { q: 'What\'s in the BPC + TB Combo vial?', a: 'A single lyophilized vial containing 5mg BPC-157 and 5mg TB-500 co-formulated under nitrogen. Each peptide is independently synthesized and HPLC-validated before blending. The COA reports purity for each peptide separately.' }, { q: 'Why co-formulate two peptides in one vial?', a: 'For comparative in-vitro assays — when a lab wants to test BPC-157 and TB-500 together on the same cell line or tissue preparation without pipetting errors or differential reconstitution timing. Single-peptide vials remain available if you need them isolated.' }, { q: 'How do I reconstitute a co-formulated vial?', a: 'Add 2–5 mL bacteriostatic water or sterile saline with gentle swirling (do not shake). Both peptides dissolve readily and are stable together in aqueous solution at 2–8°C for up to 30 days.' }, { q: 'Is the combo priced at a discount vs buying separately?', a: 'Yes. A 5mg BPC-157 vial + 5mg TB-500 vial would total $143; the combo is $119. The discount reflects the shared vial, fill, and QC cost.' }, ], 'cjc-1295-dac': [ { q: 'What does the "DAC" modification do?', a: 'DAC (Drug Affinity Complex) is a maleimidopropionyl-lysine modification that covalently binds to serum albumin, extending the peptide\'s functional half-life in in-vitro serum-containing systems from minutes to days. This makes it the preferred reference compound for long-duration GHRH receptor assays.' }, { q: 'How is CJC-1295 with DAC different from CJC-1295 without DAC?', a: 'The non-DAC version (also called "Modified GRF 1-29") has a short half-life appropriate for short-duration assays. The DAC version is designed for sustained receptor-occupancy studies. Most research labs select one or the other based on the assay timecourse, not both.' }, { q: 'Do you stack CJC-1295 with Ipamorelin in a combo vial?', a: 'Not currently as a pre-formulated product — researchers typically reconstitute each peptide separately to control molar ratios. Both single-peptide vials are in stock.' }, { q: 'What\'s the recommended storage for CJC-1295 w/ DAC?', a: 'Lyophilized: −20°C, stable 24 months. Reconstituted: 2–8°C, use within 30 days. The DAC moiety is sensitive to prolonged room-temperature exposure, so avoid repeated freeze-thaw cycles.' }, ], 'ipamorelin': [ { q: 'What makes Ipamorelin "selective" as a GH secretagogue?', a: 'Unlike non-selective secretagogues, Ipamorelin binds GHSR-1a (the ghrelin receptor) without significant cross-reactivity at prolactin, cortisol, or ACTH pathways in in-vitro receptor panels. This selectivity is why it\'s the preferred reference ligand in GHSR-1a-specific binding assays.' }, { q: 'Can I use Ipamorelin alongside CJC-1295 for research?', a: 'Yes — co-administration is a standard design in in-vitro pituitary-axis assays because the two compounds target complementary receptors (GHRH-R and GHSR-1a). Reconstitute each vial separately and combine at the bench to control molar ratios.' }, { q: 'What\'s the sequence of Ipamorelin?', a: 'Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (a pentapeptide with non-natural amino acid substitutions that confer receptor selectivity). Molecular formula C38H49N9O5, mass 711.85 g/mol.' }, { q: 'Is a smaller (1–2mg) research pack available?', a: 'Not currently — our standard fill is 5mg per vial, which is the most economical size for typical in-vitro protocols. Bulk orders (10+ vials) receive volume pricing; contact support.' }, ], 'sermorelin': [ { q: 'What is Sermorelin\'s relationship to native GHRH?', a: 'Sermorelin is the synthetic 1–29 amino-acid fragment of native human GHRH, retaining full GHRH-receptor agonist activity. It\'s the shortest GHRH analog that preserves the biological signaling motif, making it a common reference compound for receptor-binding and second-messenger assays.' }, { q: 'Why is Sermorelin acetate salt vs free base?', a: 'The acetate salt form is chemically more stable in lyophilized storage and more soluble in aqueous buffers than the free peptide. Acetate content is quantified on every lot and reported on the COA (typical range 6–10%).' }, { q: 'How does Sermorelin compare to Tesamorelin as a research tool?', a: 'Both are GHRH analogs but differ in modifications: Sermorelin is a simple 1–29 fragment; Tesamorelin adds an N-terminal trans-3-hexenoic acid group for resistance to DPP-IV cleavage. Researchers select based on assay duration — Sermorelin for short timecourses, Tesamorelin for sustained exposure studies.' }, { q: 'What\'s the shelf life of lyophilized Sermorelin?', a: '24 months at −20°C in the sealed original vial. Once reconstituted, use within 14–30 days stored at 2–8°C. The peptide is particularly sensitive to freeze-thaw cycles post-reconstitution — aliquot on first use.' }, ], 'tesamorelin': [ { q: 'Why the trans-3-hexenoic acid modification?', a: 'The N-terminal fatty-acid group on Tesamorelin blocks cleavage by dipeptidyl peptidase-IV (DPP-IV), which is the enzyme responsible for rapid degradation of native GHRH. In in-vitro serum-containing systems, this extends the peptide\'s functional half-life from minutes to hours.' }, { q: 'Is Tesamorelin identical to the clinical product Egrifta?', a: 'Clarion\'s Tesamorelin is synthesized as the same 44-amino-acid sequence with identical modifications. However, we supply it strictly as a research-use reference compound — it is not a pharmaceutical-grade finished drug product and carries no therapeutic labeling.' }, { q: 'What\'s the HPLC purity on the current lot?', a: 'Lot CP2604-X01 released at 99.1% main-peak area. The full chromatogram, identity confirmation, and peptide content (amino-acid analysis) are documented on the COA shipped with each vial.' }, { q: 'Is 10mg the only fill size?', a: 'Yes — 10mg is our standard Tesamorelin fill, selected because it\'s the most common in-vitro assay workload and provides best per-mg pricing. Contact support for bulk-order quotes (10+ vials).' }, ], 'ghk-cu': [ { q: 'Is GHK-Cu supplied as the copper complex or the free tripeptide?', a: 'Clarion supplies GHK-Cu as the copper-bound complex (GHK-Cu²⁺), which is the bioactive form used in fibroblast-signaling and extracellular-matrix research. The copper chelation is stoichiometric 1:1 and verified by UV-Vis absorbance at 525 nm.' }, { q: 'Why is the vial size 50mg (larger than other peptides)?', a: 'GHK-Cu research protocols typically use higher bench concentrations than signaling peptides, and 50mg is the most cost-effective fill for typical in-vitro experiments. The molecular weight (403.91 g/mol) also means more moles per mg than a 4kDa peptide.' }, { q: 'Does GHK-Cu require special storage vs non-copper peptides?', a: 'Store lyophilized at −20°C, protected from light (the copper complex is mildly photosensitive). Once reconstituted, keep refrigerated at 2–8°C and use within 14 days — aqueous stability is shorter than uncomplexed peptides.' }, { q: 'What\'s the research context for GHK-Cu?', a: 'GHK-Cu is a reference compound in in-vitro fibroblast proliferation, collagen-synthesis, and extracellular-matrix remodeling assays. It\'s not sold for cosmetic or topical use; our vials are research-grade reagent packaging.' }, ], 'pt-141': [ { q: 'What is the research use case for PT-141?', a: 'PT-141 (Bremelanotide) is a reference ligand in melanocortin receptor (MC3R / MC4R) binding and signaling assays. It\'s one of the most-characterized non-selective melanocortin agonists and appears in hundreds of published in-vitro studies.' }, { q: 'Why is PT-141 cyclic rather than linear?', a: 'The disulfide-bridged cyclic structure locks the peptide into its active conformation, dramatically improving both receptor affinity and in-vitro stability compared to linear analogs. The cyclization is verified by mass spectrometry on every lot.' }, { q: 'Does PT-141 bind MC1R or just MC3R/MC4R?', a: 'PT-141 is a non-selective melanocortin agonist with measurable affinity at MC1R, MC3R, MC4R, and MC5R. For MC4R-specific research, more selective ligands exist — PT-141 is preferred as a reference pan-agonist.' }, { q: 'What\'s the current lot purity?', a: 'Lot CP2604-P01 released at 99.3% HPLC main-peak. Mass confirmation by ESI-MS: 1025.18 g/mol, matching the theoretical mass for the cyclic heptapeptide.' }, ], 'semaglutide': [ { q: 'Is Clarion\'s Semaglutide the same compound as Ozempic/Wegovy?', a: 'We synthesize Semaglutide to the published 31-amino-acid sequence with the C18 fatty-acid modification. However, Clarion supplies it strictly as a research-use reference compound — it is not pharmaceutical-grade finished drug product, is not in a delivery device, and carries no therapeutic labeling.' }, { q: 'What\'s the half-life advantage vs native GLP-1?', a: 'Native GLP-1 is degraded by DPP-IV within 1–2 minutes in serum. Semaglutide\'s modifications (Aib substitution at position 8, albumin-binding C18 linker) extend in-vitro functional half-life to hours, making it ideal for sustained receptor-occupancy studies.' }, { q: 'How does Semaglutide compare to Tirzepatide for research?', a: 'Semaglutide is a single-target GLP-1R agonist; Tirzepatide is a dual GIP/GLP-1 agonist. Labs studying GLP-1R selectivity use Semaglutide; comparative metabolic-pathway research typically uses both. See our full comparison guide.' }, { q: 'Is a 2mg or 10mg size available?', a: 'Our standard fill is 5mg per vial. Bulk orders (multiple vials) receive volume pricing. Custom fills are available for institutional accounts on request.' }, { q: 'What\'s the COA release testing?', a: 'Identity by HPLC-MS, purity by HPLC (≥99.0% main-peak), peptide content by amino-acid analysis, water by Karl Fischer, acetate by ion chromatography, plus sterility and endotoxin. Released per USP <1226>.' }, ], 'tirzepatide': [ { q: 'Why is Tirzepatide called a "dual agonist"?', a: 'Tirzepatide binds both GIP and GLP-1 receptors with comparable affinity — a design intended to engage two complementary incretin pathways in a single molecule. In in-vitro comparative binding assays, it shows approximately equipotent activity at both receptors.' }, { q: 'Is Clarion\'s Tirzepatide identical to Mounjaro/Zepbound?', a: 'Same 39-amino-acid sequence with the same C20 fatty-acid modification. Clarion supplies Tirzepatide strictly as a research-use reference compound — not pharmaceutical-grade finished drug product, not in a delivery device, no therapeutic labeling.' }, { q: 'What purity do you guarantee?', a: 'All released lots are ≥99.0% HPLC main-peak area with no individual impurity >0.5%. Lot CP2604-T01 released at 99.2%. The full chromatogram is available on the COA shipped with every vial.' }, { q: 'How is Tirzepatide stored once reconstituted?', a: 'Lyophilized: −20°C, stable 24 months. Post-reconstitution: 2–8°C, use within 30 days. Aliquot to avoid freeze-thaw cycles if the reconstituted material needs to be held longer.' }, { q: 'Is Tirzepatide available in a 10mg vial?', a: 'Our standard Tirzepatide fill is 5mg. Bulk institutional orders (10+ vials) can request custom fill sizes — contact support for quoting.' }, ], 'retatrutide': [ { q: 'What makes Retatrutide a "triple agonist"?', a: 'Retatrutide binds and activates three incretin/metabolic receptors: GIP, GLP-1, and glucagon. In in-vitro receptor panels, it shows balanced activity across all three, making it a reference compound for studying multi-receptor incretin pathway research.' }, { q: 'Is Retatrutide clinically available?', a: 'As of 2026 Retatrutide is in late-stage clinical trials but not yet commercially marketed as a drug. Clarion supplies it as a research-use reference compound — not for human use, not a pharmaceutical product.' }, { q: 'Why is Retatrutide priced higher than Semaglutide or Tirzepatide?', a: 'Retatrutide\'s synthesis involves more complex modification chemistry and the market supply is limited. Our 10mg fill (larger than our other GLP-1 analogs) also contains twice the peptide mass per vial.' }, { q: 'Can Retatrutide be used alongside Semaglutide in comparative assays?', a: 'Yes — comparative dose-response studies across multiple incretin agonists are a common in-vitro research design. Reconstitute each peptide separately and apply at matched molar concentrations.' }, ], 'nad-plus': [ { q: 'Is Clarion\'s NAD+ peptide or small molecule?', a: 'NAD+ (nicotinamide adenine dinucleotide) is a small-molecule dinucleotide cofactor, not a peptide. We include it in our catalog because many peptide-research labs also run NAD-dependent enzyme and sirtuin assays and benefit from sourcing both from one supplier.' }, { q: 'What grade and purity is the NAD+?', a: 'Research-grade, ≥99.0% HPLC purity. We supply the free-acid form as a lyophilized powder. Molecular formula C21H27N7O14P2, mass 663.43 g/mol. Full COA with identity, purity, and water content on every lot.' }, { q: 'Is the 500mg fill the right size for typical in-vitro assays?', a: 'Yes — NAD+ enzyme and sirtuin assays typically work at millimolar concentrations, so a 500mg fill supports many plate-based experiments. Bulk (multi-gram) orders available on request.' }, { q: 'How should NAD+ be stored?', a: 'Lyophilized NAD+ is stable at −20°C, protected from light and moisture, for 24 months. In aqueous solution, it hydrolyzes — reconstitute immediately before use and discard unused solution within 24 hours.' }, ], 'mots-c': [ { q: 'Where does the MOTS-c sequence come from?', a: 'MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region — one of the first characterized mitochondrial-derived peptides. It\'s a reference compound in AMPK-pathway, mitochondrial-function, and metabolic in-vitro research.' }, { q: 'What\'s the current HPLC purity?', a: 'Lot CP2604-O01 released at 99.0% main-peak area by HPLC. Mass confirmed by ESI-MS. Full chromatogram and analytical data on the COA.' }, { q: 'Does MOTS-c require special reconstitution?', a: 'Standard protocol: reconstitute in bacteriostatic water or sterile saline at 1–2 mg/mL. MOTS-c is fully soluble in aqueous buffers. Once reconstituted, store at 2–8°C and use within 30 days, or aliquot and freeze.' }, { q: 'Is MOTS-c studied alongside NAD+?', a: 'Yes — MOTS-c and NAD+ both appear in mitochondrial-function and AMPK-pathway research designs. Some labs source both from the same release lot to simplify chain-of-custody for their experiments.' }, ], }; /* ---------- FAQ accordion component used on the PDP ---------- */ function ProductFAQ({ slug }) { const faqs = PRODUCT_FAQS[slug]; const [openIdx, setOpenIdx] = React.useState(0); if (!faqs || !faqs.length) return null; return (
QUESTIONS

Frequently asked

{faqs.map((f, i) => { const open = openIdx === i; return (
{open && (
{f.a}
)}
); })}
); } Object.assign(window, { PRODUCT_FAQS, ProductFAQ });